ScinoPharm Taiwan Ltd
TWSE:1789
ScinoPharm Taiwan Ltd
Cost of Revenue
ScinoPharm Taiwan Ltd
Cost of Revenue Peer Comparison
Competitive Cost of Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
ScinoPharm Taiwan Ltd
TWSE:1789
|
Cost of Revenue
-NT$2B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
0%
|
CAGR 10-Years
3%
|
|
Y
|
YungShin Global Holding Corp
TWSE:3705
|
Cost of Revenue
-NT$4.1B
|
CAGR 3-Years
1%
|
CAGR 5-Years
0%
|
CAGR 10-Years
-4%
|
Formosa Laboratories Inc
TWSE:4746
|
Cost of Revenue
-NT$2.4B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-1%
|
|
S
|
SCI Pharmtech Inc
TWSE:4119
|
Cost of Revenue
-NT$853.8m
|
CAGR 3-Years
15%
|
CAGR 5-Years
6%
|
CAGR 10-Years
0%
|
Lotus Pharmaceutical Co Ltd
TWSE:1795
|
Cost of Revenue
-NT$7.7B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
-22%
|
|
Standard Chem & Pharm Co Ltd
TWSE:1720
|
Cost of Revenue
-NT$3.6B
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-7%
|
See Also
What is ScinoPharm Taiwan Ltd's Cost of Revenue?
Cost of Revenue
-2B
TWD
Based on the financial report for Dec 31, 2023, ScinoPharm Taiwan Ltd's Cost of Revenue amounts to -2B TWD.
What is ScinoPharm Taiwan Ltd's Cost of Revenue growth rate?
Cost of Revenue CAGR 10Y
3%
Over the last year, the Cost of Revenue growth was 2%. The average annual Cost of Revenue growth rates for ScinoPharm Taiwan Ltd have been -4% over the past three years , and 3% over the past ten years .